According to researchers at the Klagenfurt Clinic in Austria, CBD has shown promising results for Covid-19 ICU patients by decreasing inflammation and reducing the duration to recovery.
The trial used Cannabidiol throughout a three-week course of treatment for Covid-19 sufferers at the hospital’s ICU unit. The clinic’s head of intensive care medicine, Rudolf Likar, began by administering a 200 milligram dose of CBD each day, later increasing the dose to 300 milligrams. “We have seen that the inflammation parameters in the blood go down and people leave the hospital faster than the comparison group,” Likar said. “CBD supports the immune system,” he revealed.
As noted in a local Austrian newspaper, Likar believes that the cannabidiol found in CBD closes off the ACE2 receptor through which SARS-CoV-2 enters human cells and then self-replicates. The clinical trial suggests that the inflammatory effects found in CBD oil can be even more beneficial compared to other commonly-used drugs, due to cannabidiol’s ability to cross the blood-brain barrier and avert some of the more extreme neurological damage that stems from long-term Covid-19 infections.
The Klagenfurt Clinic is still continuing with the study of CBD’s inflammatory effects, but thus far, the results appear to be promising. “We are now evaluating the data and the data is looking relatively good. We’ll probably use this routinely now because it doesn’t have any side effects,” Likar explained, while noting that a similar study on the effects of CBD on Covid-19 is currently underway in Israel as well.
Information for this briefing was found via the Upper Austrian News. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.
